Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tetrahydroisoquinoline-3-formyl-K (GRPAK) RGDV and synthesis, activity and application thereof

A technology of tetrahydroisoquinoline and isoquinoline, applied in the preparation of antithrombotic drugs, thrombolytic drugs and drugs for the treatment of ischemic stroke, in the field of thrombolytic activity, can solve the problem of no effective drugs

Active Publication Date: 2017-05-03
北京恒润泰生医药科技有限公司
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the clinical treatment of ischemic stroke faces the reality that there are no effective drugs, especially for patients with strokes lasting more than 4 hours, either dying or being disabled

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tetrahydroisoquinoline-3-formyl-K (GRPAK) RGDV and synthesis, activity and application thereof
  • Tetrahydroisoquinoline-3-formyl-K (GRPAK) RGDV and synthesis, activity and application thereof
  • Tetrahydroisoquinoline-3-formyl-K (GRPAK) RGDV and synthesis, activity and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1 liquid phase connection peptide reaction general method

[0023] The N-terminal protected raw material was dissolved in anhydrous DMF, and N-hydroxybenzotriazole (HOBt) was added to the resulting solution. N,N-dicyclohexylcarbodiimide (DCC) dissolved in anhydrous DMF was slowly added under ice-cooling, and stirred at 0°C for 15 minutes to obtain a reaction solution (I). The carboxy-terminally protected raw material was also dissolved in anhydrous DMF, adjusted to pH 9 with N-methylmorpholine (NMM), then mixed with the reaction solution (I), maintained at pH 9 with N-methylmorpholine, and stirred at room temperature for 10 hour, TLC monitors that after the raw material point disappears, the reaction mixture is filtered, and the filtrate is concentrated under reduced pressure to obtain a viscous substance that is dissolved in ethyl acetate, and the solution obtained is successively washed with 5% NaHCO 3 Aqueous wash, 5% KHSO 4 Washing with aqueous solution...

Embodiment 2

[0024] Embodiment 2 removes Boc general method

[0025] The Boc-protected peptide was dissolved in a small amount of anhydrous ethyl acetate, and a solution of hydrogen chloride in ethyl acetate (4M) was added with stirring in an ice bath. After TLC showed that the raw material point disappeared, the reaction solution was repeatedly pumped dry with a water pump to remove hydrogen chloride gas, and the residue was repeatedly ground with petroleum ether or anhydrous ether to obtain the target compound.

Embodiment 3

[0026] Embodiment 3 debenzyl ester general method

[0027] Peptide benzyl ester with CH 3 OH was dissolved, and an aqueous solution of NaOH (2M) was slowly added dropwise with stirring in an ice bath. The temperature of the reaction solution was maintained at 0° C. in an ice bath, and TLC showed that the starting material disappeared. The reaction solution was adjusted to neutrality with 1M hydrochloric acid, methanol was removed under reduced pressure, and acidified to pH 2 with 1M hydrochloric acid, the solution was extracted with ethyl acetate, and the combined ethyl acetate phase was washed with saturated NaCl aqueous solution to neutrality, and washed with anhydrous Water Na 2 SO 4 Dry, filter, and concentrate the filtrate under reduced pressure to obtain the target compound.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The inside diameter ofaaaaaaaaaa
The inside diameter ofaaaaaaaaaa
Outer diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses N-(3S-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-formyl)-Lys (Gly-Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val and a preparation method, antithrombus activity and thrombolytic activity thereof and also discloses the effect of the compound on treatment of rats suffering from cerebral ischemia. The invention discloses application of the compound in preparation of antithrombus medicines, thrombolytic medicines and medicines for treating ischemic stroke.

Description

technical field [0001] The present invention relates to N-(3S-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-formyl)-Lys(Gly-Arg-Pro -Ala-Lys)-Arg-Gly-Asp-Val, relating to its preparation method, relating to its antithrombotic activity, relating to its thrombolytic activity, relating to its effect on treating cerebral ischemia rats, thus the present invention relates to it Application in the preparation of antithrombotic drugs, thrombolytic drugs and drugs for treating ischemic stroke. Background technique [0002] Ischemic stroke is a relatively common and serious cerebrovascular disease, characterized by high incidence, high mortality, high disability rate and high recurrence rate. At present, the clinical treatment of ischemic stroke faces the reality that there is no effective drug, especially for patients with stroke lasting more than 4 hours, either dying or being disabled. It is an important clinical need to invent drugs that are effective for patients ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/64A61K38/12A61P7/02A61P9/10
Inventor 彭师奇赵明李姗彭莉
Owner 北京恒润泰生医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com